Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Significant Growth in Short Interest

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 1,166,300 shares, a growth of 39.7% from the December 15th total of 835,100 shares. Based on an average daily trading volume, of 2,100 shares, the short-interest ratio is presently 555.4 days.

Zealand Pharma A/S Trading Down 0.4 %

Shares of ZLDPF traded down $0.43 during mid-day trading on Wednesday, reaching $97.10. The company had a trading volume of 990 shares, compared to its average volume of 915. Zealand Pharma A/S has a fifty-two week low of $64.10 and a fifty-two week high of $141.74. The firm has a fifty day simple moving average of $104.95 and a 200-day simple moving average of $119.05. The stock has a market cap of $5.00 billion, a price-to-earnings ratio of -39.96 and a beta of 0.89. The company has a current ratio of 35.49, a quick ratio of 35.49 and a debt-to-equity ratio of 0.03.

Wall Street Analyst Weigh In

Separately, JPMorgan Chase & Co. started coverage on Zealand Pharma A/S in a report on Friday, November 8th. They set an "overweight" rating on the stock.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.